The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow‐up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation - Menne, Jan; Ritz, Eberhard; Ruilope, Luis M.; Chatzikyrkou, Christos; Viberti, Giancarlo; Haller, Hermann (Journal of the American Heart Association, 2014)
Gesehen am 22.09.2020